Fycompa
Parkinson's Disease
Eisai Inc.Phase 3Dormant
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 73/ 100
Competitive context
256 Active assets in the Parkinson's Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Safinamide Zambon SpA | Phase 4 | A |
Cvt-301 Acorda Therapeutics | Phase 3 | A |
Tvp-1012 Guangzhou Henovcom Bioscience Co. Ltd. | Phase 4 | BBB |
Pardoprunox Abbott Products | Phase 3 | BBB |
Istradefylline Georgetown University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Fycompa is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →